{"id":405289,"date":"2019-09-23T00:00:00","date_gmt":"2019-09-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0026-2019-biopharma-axial-spondyloarthritis-current-treatment-current-treatment-physician-insights-axial\/"},"modified":"2026-04-27T23:38:45","modified_gmt":"2026-04-27T23:38:45","slug":"cutrim0026-2019-biopharma-axial-spondyloarthritis-current-treatment-current-treatment-physician-insights-axial","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0026-2019-biopharma-axial-spondyloarthritis-current-treatment-current-treatment-physician-insights-axial\/","title":{"rendered":"Axial Spondyloarthritis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Axial Spondyloarthritis (EU5)"},"content":{"rendered":"<p>The axial spondyloarthritis (<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (<abbr title=\"ankylosing spondylitis\">AS<\/abbr>), has expanded beyond those with spinal abnormalities detectable by radiography and into the population of nonradiographic (nr-<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>) patients. <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors are the well-established biologics in <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> patients who do not respond to conventional therapies. The approval of the <abbr title=\"interleukin\">IL<\/abbr>-17 inhibitor Cosentyx in the <abbr title=\"European Union\">EU<\/abbr> in 2015 marked the first non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr> biologic for <abbr title=\"ankylosing spondylitis\">AS<\/abbr> and the first drug with a new mechanism of action in over a decade. The launch of biosimilar <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors, especially biosimilar etanercept in 2016 and biosimilar adalimumab in 2018, has and will continue to impact the market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the brand-level patient share of key biologics (Humira, Enbrel, Cimzia, Simponi, Remicade, Cosentyx) in <abbr title=\"ankylosing spondylitis\">AS<\/abbr> and nr-<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>? How are different biologics positioned in surveyed physicians\u2019 treatment algorithms?<\/li>\n<li>What are the common treatment scenarios before initiating the different biologics? What are the recent\/anticipated changes in the prescribing of biologics?<\/li>\n<li>What are the key drivers and constraints for physicians to prescribe biologics to their <abbr title=\"ankylosing spondylitis\">AS<\/abbr> and nr-<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> patients? What factors drive therapy discontinuation and switching?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p>Geographies: France, Germany, Italy, Spain, United Kingdom.<\/p>\n<p>Primary Research:\u00a0 Survey of 251 rheumatologists in France, Germany, Italy, Spain, and the United Kingdom.<\/p>\n<p>Key Drugs Covered:\u00a0Humira \/ biosimilar, Enbrel \/ biosimilar, Cimzia, Simponi, Remicade \/\u00a0biosimilar, Cosentyx.<\/p>\n<p>Key insights\u00a0provided: Factors influencing disease management and treatment decisions, drivers and constraints of treatment selection, physician-reported treatment practices\u00a0and brand-level patient shares, rationale for changes in treatment approach, physician insight on persistency and compliance, and physician-reported recent \/ anticipated changes in brand usage or treatment approach.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n","protected":false},"template":"","class_list":["post-405289","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-therapy-areas-rheumatology","biopharma-product-current-treatment","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/405289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/405289\/revisions"}],"predecessor-version":[{"id":405621,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/405289\/revisions\/405621"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=405289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}